Page 4

- 35. Chimeric RSV further comprising a nucleotide modification specifying a phenotypic change in immunogenicity,
- 36. Chimeric RSV wherein the genome or antigenome is modified to encode a cytokine,
- 37. Chimeric RSV wherein the genome or antigenome is modified to encode a T-helper epitope,
- 38. Chimeric RSV wherein the genome or antigenome is modified to encode a restriction site marker, and
- 39. Chimeric RSV wherein the genome or antigenome is modified to encode a protein of a microbial pathogen.

Applicants elect to prosecute Group I, claims 1-30, 35 and 46-65, and species 11, Chimeric RSV with a G heterologous gene, with traverse. The present election obviates the Restriction and Species Election Requirements, without need to further consider the merits of the Restriction. Therefore, the present election is made without prejudice or acquiescence to any position taken by the Office concerning the possible nature and/or existence of distinct inventions among the originally presented claims. Applicants traverse the Restriction and Species Election Requirements on these limited grounds and reserve the right to file a divisional or related application to the claims of non-elected groups.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 206-467-9600.

Respectfully submitted,

Dated: __ \

1/22/00

Jeffrey J. King

Customer Number 20350

Peter L. Collins, et al. Application No.: 09/291,894

Page 5

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834 Tel: (206) 467-9600

Fax: (415) 576-0300 JJK:lmp

SE 5006550 v1



RECEIVED

JAN 26 2001

TECH CENTER 1600/2900